ClinicalTrials.gg
CompletedNCT03268226FRIUpdated Mar 4, 2020

Functional Respiratory Imaging Study (FRI)

A Phase 3 interventional study of Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium in Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 5 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2020-03-04.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. Beclomethasone · Pulmonary Disease, Chronic Obstructive.

Enrollment
8th of 13
20 · median 24
Started
2017
the only one that year
Phase 3
3 of 13
none open now
Registered
12th of 13
by date
Lead sponsor
6 of 13
Chiesi Farmaceutici S.p.A.

Among the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive, this one is the 8th largest by enrollment, is the only one that started in 2017, is one of 3 in phase 3, and was the 12th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

The purpose of this study is to evaluate the effect of inhaled extrafine CHF5993 pMDI on airway volumes, and resistance, by Functional Respiratory Imaging (FRI), in COPD patients

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject's written obtained prior to any study-related procedure.
  2. Male or Female patients aged ≥ 40 years.
  3. Smoking history: of at least 10 pack-years (pack-year= number of cigarettes per day x number of years/20).
  4. Smoking status: current or ex-smokers. Previous smokers are defined as those who have stopped smoking for at least 24 weeks prior to screening visit. (Pipe and/or cigar and/or e-cigarettes smoking cannot be used to calculate pack-year history). If the subjects undergo smoking cessation therapy, it must be completed 3 months prior to study entry.
  5. Patients with documented COPD at least 12 months according to GOLD 2017.
  6. Post-bronchodilator (BD) decreased Tiffeneau index: /FVC \< 0.70.
  7. Patients who present post- BD FEV1 less than 50 % of predicted.
  8. Patients who present (Functional residual capacity) FRC ≥120% predicted.
  9. Patients who present CAT assessment ≥10.
  10. Patients on stable respiratory medications for at least 3 months prior to screening with non extrafine extemporary triple combination. The possible combination therapies prior to screening are:

    • fluticasone plus salmeterol plus tiotropium
    • fluticasone plus salmeterol plus glycopyrronium
    • fluticasone plus salmeterol plus umeclidinium
    • fluticasone plus vilanterol plus tiotropium
    • fluticasone plus vilanterol plus glycopyrronium
    • fluticasone plus vilanterol plus umeclidinium;
  11. (BMI) between 18.0 and 32.0 kg/m2 (extremes included) at the screening visit..
  12. Ability to understand the study procedures and the risks involved and ability to be trained with pMDI training inhalers to use the devices correctly.
  13. fulfilling one of the following criteria:

    1. WOCBP with fertile male partners: they and/or their partner must be willing to use a highly effective method from the signature of the informed consent and until the follow-up visit or
    2. WOCBP with non-fertile male partners (contraception is not required in this case).

    For the definition of WOCBP and of fertile men and the list of highly effective birth control methods, refer the CTFG guidance for more detailed information

  14. Female patients of non-childbearing potential defined as physiologically incapable of becoming pregnant (i.e. or permanently sterile; e.g. amenorrehic for ≥12 consecutive months without alternative medical cause). Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy (40). If indicated, as per investigator's request, post-menopausal status may be confirmed by follicle-stimulating hormone levels (according to local laboratory ranges).

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women.
  2. Patients with history or current diagnosis of asthma.
  3. Medical history or current diagnosis of allergic rhinitis or atopy (atopy which may have risen or impacted the efficacy of the study treatment according to Investigator's judgment).
  4. Patients requiring use of the following medications:

    1. Systemic for exacerbation in the 4 weeks prior to screening;
    2. Patients with a moderate or severe COPD exacerbation [i.e. resulting in the use of systemic corticosteroids (oral/IV/IM) and/or or antibiotics or need for hospitalisation within 6 weeks prior to screening];
    3. A course of antibiotics for COPD exacerbation longer than 7 days in the 4 weeks prior to screening;
    4. c-Phosphodiesterase-4 (PDE-4) inhibitors in the 4 weeks prior to screening;
    5. Use of antibiotics for a lower respiratory tract infection (e.g. pneumonia) in the 4 weeks prior to screening;
  5. Patients treated with non-cardio-selective β-blockers in the week prior to screening.
  6. Patients treated with long-acting anti-histamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study.
  7. Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia.
  8. Known respiratory disorders other than COPD which may impact the efficacy of the study treatment according the Investigator's judgment. (This could include but is not limited to α-1 antitrypsin deficiency, active tuberculosis, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension and interstitial lung disease).
  9. Lung cancer or history of lung cancer: patients with a diagnosis of lung cancer or a history of lung cancer.
  10. Lung resection: subjects with a history of lung volume resection.
  11. Subjects who have a cardiovascular condition such as, but not limited to unstable ischemic heart disease, Class III/IV left ventricular failure, acute ischemic heart disease in the last year prior to study screening, which may impact the safety of the subject or the evaluation of the result of the study according to the Investigator's judgment; history of atrial fibrillation, history of sustained and non sustained cardiac arrhythmias diagnosed within 24 weeks prior to study entry not controlled with therapy.
  12. criteria: any abnormal 12-lead ECG that in the Investigator's opinion would affect the efficacy or safety evaluation or place the patients at risk. Male patients with a >450ms and female patients with a QTcF >470ms at screening and/or baseline visits are not eligible.
  13. Medical history or current diagnosis of narrow-angle glaucoma, clinically relevant prostatic hypertrophy or bladder neck obstruction that in the opinion of the Investigator would have prevented use of anticholinergic agents.
  14. History of to M3 antagonists, β2-agonist, corticosteroids or any of the contained in any of the formulations used in the study which may raise contra-indications or impacted the efficacy of the study treatment according to the Investigator's judgment.
  15. Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease which may have impacted the efficacy or the safety of the study treatment according to Investigator's judgment.
  16. Patients with serum potassium levels \< 3.5 mEq/L (or 3.5 mmol/L).
  17. Unstable concurrent disease: e.g. uncontrolled hyperthyroidism, uncontrolled diabetes mellitus or other endocrine disease; uncontrolled gastrointestinal disease (e.g. active peptic ulcer); uncontrolled neurological disease; uncontrolled hematological disease; uncontrolled disorders, or other which may impact the feasibility of the results of the study according to Investigator's judgment.
  18. History of alcohol abuse and/or substance/drug abuse within 12 months prior to screening.
  19. Drugs with hepatoxic potential: Patients receiving treatment with any drug known to have a well defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole) within the previous 3 months before the screening visit.
  20. Changes in dose, schedule, formulation or product of oral xanthine derivatives (e.g. Theophylline) in the month prior screening visit.
  21. Participation in an trial: patients who have received any investigational drug within the 30 days (60 days for biologics) before the screening visit or a more appropriate time as determined by the investigator (e.g. approximately 5 half-lives of the investigational drug whatever is longer).
  22. Treatment with strong inhibitors (e.g. erythromycin, itraconazole) within 4 weeks prior to study entry.
  23. Serology at the screening positive for HIV1 or HIV2 and positive results for Hepatitis which indicates acute or chronic (i.e. positive HB surface antigen HBsAg, positive and/or positive HB core antibody anti-HBc) or (positive HCV antibody).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    CHF5993

    Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI

    Drug: Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium

Interventions

  • DrugBeclometasone dipropionate/Formoterol Fumarate/Glycopyrronium

    Drug pages: Beclomethasone · Formoterol · Glycopyrrolate

    An inhaled dose of CHF 5993 pMDI 100+6+12.5 μg twice a day (Total daily dose: BDP 400 μg / FF 24 μg / GB 50 μg)

06

What researchers measure

Primary outcomes

  1. Specific image-based airway volumes (siVaw)

    CT-based airway volumes normalized by the lung volume

    Time frame: Change from baseline at 24 Weeks.

  2. Specific image-based airway resistance (siRaw)

    CFD-based airway resistance normalized by the lung volume

    Time frame: Change from baseline at 24 Weeks.

Secondary outcomes

  1. Internal Airflow Distribution

    calculated using thorax HRCT

    Time frame: On Week 0, Week 12, and on Week 24

  2. Air Trapping

    calculated using thorax HRCT

    Time frame: On Week 0, Week 12, and on Week 24

  3. Emphysema

    calculated using thorax HRCT

    Time frame: On Week 0, Week 12, and on Week 24

  4. Airway Wall Volume

    calculated using thorax HRCT

    Time frame: On Week 0, Week 12, and on Week 24

  5. Blood vessel density

    calculated using thorax HRCT

    Time frame: On Week 0, Week 12, and on Week 24

  6. Ventilation/perfusion matching

    calculated using thorax HRCT

    Time frame: On Week 0, Week 12, and on Week 24

  7. Aerosol Deposition

    calculated using thorax HRCT

    Time frame: On Week 0, Week 12, and on Week 24

  8. Functional Dyspnea

    mMRC dyspnea scale

    Time frame: On Week 0, Week 12, and on Week 24

  9. Quality of life

    Saint George Respiratory Questionnaire (SGRQ)

    Time frame: On Week 0, Week 12, and on Week 24

  10. CAT score

    8-items unidimensional questionnaire

    Time frame: On Week 0, Week 12, and on Week 24

  11. Dyspnea

    Borg CR10

    Time frame: On Week 0, Week 12, and on Week 24

  12. Dynamic lung volumes

    calculated using spirometry

    Time frame: On Week 0, Week 12, and on Week 24

  13. Static lung volumes

    calculated using body plethysmography

    Time frame: On Week 0, Week 12, and on Week 24

  14. airway resistances

    calculated using body plethysmography

    Time frame: On Week 0, Week 12, and on Week 24

Other outcomes

  1. exercise tolerance

    cycling endurance test (CET)

    Time frame: On Week 0, Week 12, and on Week 24

07

Study locations

5 sites
  • SGS CPU Antwerpen
    Antwerpen, Belgium
  • AZ Saint-Maarten
    Duffel, Belgium
  • Centre medical Erpent - Residence
    Erpent, Belgium
  • Heilige Familie AZ
    Reet, Belgium
  • National Koranyi Institute for TB and Pulmonology
    Budapest, Hungary
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jan 2019, 14 months.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 14 months is below that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2017
First posted
Aug 31, 2017
StartActual
Nov 20, 2017
Primary completionActual
Jan 30, 2019
CompletionActual
Jan 30, 2019
Last update
Mar 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03268226
Responsible party
Sponsor
First posted
Aug 31, 2017
Start date
Nov 20, 2017
Primary completion
Jan 30, 2019
Completion
Jan 30, 2019
Last update
Mar 4, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Beclomethasone · Formoterol · Glycopyrrolate

Start the discussion